Zynga, Inc. Message Board
- Reply to
" We Are Encouraged By ACAD Commentray on Outside Interest From Pharma Co's" LINK
by guytrader301 •May 7, 2013 1:52 AMwe then announce this at earnings.. Can't even imagine the spike.
- Reply to
A Joke To Think We'd Go Down On Earnings. Now Irreverent , Drug Is Approved.
by guyhasconquered •May 7, 2013 1:24 AMTHE GAME HAS CHANGED...approval granted.
-
- Reply to
A Joke To Think We'd Go Down On Earnings. Now Irreverent , Drug Is Approved.
by guyhasconquered •May 7, 2013 1:24 AMthat is how you spell it chump, he is correct..what never heard the word??
- Reply to
LOVAZA RAISES LDL TO %45 . VASCEPA LOWERS LDL-C ,, LOVAZA DOES NOT. LINK
by ccharles792 •May 3, 2013 3:37 PMno brainer Dr going to prescribe drug that lowers the LDL not Raises Them 45%
- Reply to
Brian Nichols Article : AMRN Has Great Upside. // linked
by terridiamond158 •May 3, 2013 3:58 PMlove brian great analyst
-
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
By GlobeNewswire
"This sNDA approval of BASF as a supplier of Vascepa follows the recent sNDA approval to add Chemport, Inc. as a Vascepa API supplier and brings the number of approved Vascepa API suppliers to three. The BASF approval represents an additional step toward the goal of expanding our global supply chain to support Vascepa demand, diversify our supply base, and ensure cost-efficient supply. In addition, Amarin has plans for the submission of a fourth planned supplier in 2013 - Reply to
Sales Must Be Good, AMRN Starting Plans For 4th Supplier. // posted.
by terridiamond158 •May 4, 2013 5:22 AMthanks
-
The chance of the FDA approving this 2nd indication is high in our view. This would be the first approval for this class of drug in this setting which would provide a meaningful competitive advantage to the only other approved competitor from GSK. An approval in this broader indication could rekindle discussions with potential suitors for either partnership or potential takeout. We do believe that the full potential of this news could be mitigated by the upcoming 1Q:13 earnings. Target price $13.
-
Wall Street 5/1/13
Leerink maintains an Outperform rating on shares.of Allergan -
Some of the subjects likely to get scrutinized when Facebook (FB -1.5%) delivers its Q1 report...
- Reply to
Only PDP Drug for Parkinson in Us Europe & Many Countries Will Be Alot More Than $12
by thegreen_o •May 1, 2013 10:59 AMcouldn't agree more
- Reply to
A Stock Like VRTX Makes U Realize How Extreme Undervalued ACAD Is.
by sharkman683 •May 1, 2013 11:29 AMgood point.
-
that's what going on here
-
- Reply to
Article Says Analysts Raising ACAD Targets from $18 to $20 LINKED
by ytodd36 •Apr 30, 2013 1:39 AMgood info. been doing DD looks good and cheap.
- Reply to
Back In. LMAO Same 3 Shorts Here Posting, Trapped From a Month Ago.
by theman111knows •Apr 29, 2013 1:57 PMyes you are the same three stooges
- Reply to
Win-Win for Investors. ACAD Makes Billions Or Buyout.
by totradetime •Apr 22, 2013 11:44 AMgood post !!!
-
great article.. now everyone knows real story : )